Literature DB >> 12921114

Cellsorba.

Hiroshi Shibata1, Toshiji Kuriyama, Naokuni Yamawaki.   

Abstract

Cellsorba is a leukocyte removal filter developed by Asahi Medical Co., which adsorbs white blood cells through the perfusion of peripheral blood by means of simple extracorporeal circulation. Leukocytapheresis (LCAP) therapy using the Cellsorba column has been reported to show therapeutic effects for many autoimmune related and inflammatory diseases, such as inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, neurologic disease, and so on. At present, Cellsorba is listed as a medical device covered by the Japanese national health insurance system for the treatment of active ulcerative colitis (UC) in Japan, and contributes to the improvement of quality of life in many UC patients. This paper reviews the use of Cellsorba and introduces several reports on therapeutic results.

Entities:  

Mesh:

Year:  2003        PMID: 12921114     DOI: 10.1046/j.1526-0968.2003.00009.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  7 in total

1.  Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon.

Authors:  Koji Sawada; Akimitsu Egashira; Kunio Ohnishi; Ken Fukunaga; Takeshi Kusaka; Takashi Shimoyama
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

Review 2.  Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults.

Authors:  Gerda C Leitner; Harald Vogelsang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

3.  Cytapheresis as a Non-Pharmacological Therapy for Inflammatory Bowel Disease.

Authors:  Takayuki Matsumoto; Ken Fukunaga; Koji Kamikozuru; Katsutoshi Tozawa; Yoko Yokoyama; Takeshi Kusaka; Kunio Onishi; Hiroto Miwa; Shiro Nakamura
Journal:  Transfus Med Hemother       Date:  2007-12-21       Impact factor: 3.747

4.  Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients.

Authors:  Ken Fukunaga; Yoshihiro Fukuda; Yoko Yokoyama; Kunio Ohnishi; Takeshi Kusaka; Tadashi Kosaka; Nobuyuki Hida; Yoshio Ohda; Hiroto Miwa; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2006-06       Impact factor: 7.527

5.  Leukocytapheresis Therapy Improved Cholestasis in a Patient Suffering from Primary Sclerosing Cholangitis with Ulcerative Colitis.

Authors:  Minoru Itou; Keiichi Mitsuyama; Takumi Kawaguchi; Yoshinobu Okabe; Hideya Suga; Junya Masuda; Hiroshi Yamasaki; Kotaro Kuwaki; Eitaro Taniguchi; Masaru Harada; Osamu Tsuruta; Michio Sata
Journal:  Case Rep Gastroenterol       Date:  2009-04-15

6.  Selective Granulocyte and Monocyte Apheresis as a Non-Pharmacological Option for Patients with Inflammatory Bowel Disease.

Authors:  Gerda C Leitner; Nina Worel; Harald Vogelsang
Journal:  Transfus Med Hemother       Date:  2012-07-31       Impact factor: 3.747

7.  Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis--results of a randomized pilot trial.

Authors:  Jörg Emmrich; Sebastian Petermann; Dietrich Nowak; Ingolf Beutner; Peter Brock; Reinhard Klingel; Patrick Mausfeld-Lafdhiya; Stefan Liebe; Wolfgang Ramlow
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.